Quick Answer
Anika Therapeutics, Inc. reported Long Term Debt of $8.00 million for the year ending 2012.
- Anika Therapeutics, Inc. showed a decrease of -16.7% in Long Term Debt from 2011 to 2012.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2014.
- XBRL data for this metric is available from 2010 to 2012 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $10.00 million | Q1 2012: $9.20 million | Q2 2012: $8.80 million | Q3 2012: $8.40 million | Q1 2013: $7.60 million | Q2 2013: $7.20 million | Q3 2013: $6.80 million | Q4 2019: $0.00 | Q2 2020: $50.00 million | Q3 2020: $25.00 million.
- Over the full 3 years of available data (2010 to 2012), Anika Therapeutics, Inc.'s Long Term Debt has declined by 28.6%.
- Historical annual values: Fiscal year 2012: $8.00 million | Fiscal year 2011: $9.60 million | Fiscal year 2010: $11.20 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: